CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

You are here

Products

back to search results

Mesothelin (Mesothelial Marker) [MSLN/2131]

Product group: Primary
Monoclonal/ Polyclonal: Monoclonal
Clone: MSLN/2131
Host: Mouse
Isotype: IgG2b
Application: Immunohistochemistry (IHC)
Application notes: Prediluted
Conjugation Type: Unconjugated
Lightchain type: Kappa
Reactivity: Human
General notes: Localization: membrane, secreted.
Buffer: citrate pH6.0
UNSPSC code: 12352203

The mesothelin gene encodes a 69-kDa precursor protein that is processed to a 40-kDa glycosylphosphatidylinositol (GPI)-anchored protein, the mature mesothelin, present on the cell surface. Its biological function is not known, but recent studies have shown that it forms a strong and specific complex with MUC16; a binding which has been suggested to be the basis of ovarian cancer metastasis. Mesothelin is present on normal mesothelial cells lining the pleura, peritoneum, and pericardium. In tumors, overexpression of Mesothelin has been observed in mesotheliomas, and other tumors including ovarian, pancreatic carcinomas, and cholangiocarcinoma. By using immunotoxin targeting immunotherapy, mesothelin has also been reported as a new therapeutic target in various types of cancers, such as human cholangiocarcinoma. (Shipping Cost: €200.00)

Mesothelin (Mesothelial Marker) [MSLN/2131]

The mesothelin gene encodes a 69-kDa precursor protein that is processed to a 40-kDa glycosylphosphatidylinositol (GPI)-anchored protein, the mature mesothelin, present on the cell surface. Its biological function is not known, but recent studies have shown that it forms a strong and specific complex with MUC16; a binding which has been suggested to be the basis of ovarian cancer metastasis. Mesothelin is present on normal mesothelial cells lining the pleura, peritoneum, and pericardium. In tumors, overexpression of Mesothelin has been observed in mesotheliomas, and other tumors including ovarian, pancreatic carcinomas, and cholangiocarcinoma. By using immunotoxin targeting immunotherapy, mesothelin has also been reported as a new therapeutic target in various types of cancers, such as human cholangiocarcinoma.